J. Cortes

发表

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

P. Kristel, C. Caldas, O. Rueda, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

L. Carey, A. Bardia, H. Rugo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

B. Kiely, L. Norton, K. Gelmon, 2020, Annals of Oncology.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial

B. Cantos, N. Martínez, E. Ciruelos, 2022, Annals of Oncology.

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

N S El Saghir, L Biganzoli, N Harbeck, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

OP-ANNO180192 1634..1657

L. Norton, L. Carey, K. Gelmon, 2018 .

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

A. Iafrate, E. Felip, P. Nuciforo, 2014 .

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

R. Gray, T. Powles, C. Wilson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Shaughnessy, O. J., L. Carey, 2022 .

VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

P. Fasching, L. Pusztai, C. Denkert, 2021 .

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

C. Perou, L. Carey, A. Wolff, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

C. Sotiriou, I. Bièche, D. Juric, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

T. Sørlie, M. J. van de Vijver, C. Sotiriou, 2012 .

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Readthrough response of pathogenic premature termination codons at PTEN gene: implications in precision therapy for PHTS patients.

V. J. Cid, A. Erramuzpe, J. Cortés, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.